Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

NCT02342548 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
188
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated on 15DEC2016 due to study A8241021 showing no significant difference on primary endpoint between PF-02545920 \& placebo. No safety concerns.

Conditions

Interventions

Sponsor

Pfizer